There are currently 95 clinical trials in Glendale, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Glendale Adventist Medical Center, Behavioral Research Specialists, LLC, Glendale Memorial Hospital and Health Center and Global Research Management. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT06514001
Recruiting
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Global Research Management, Glendale, California
Conditions: Alzheimer Disease
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 217, Glendale, California
Conditions: Major Depressive Disorder
Register for Updates
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896
Recruiting
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/08/2024
Locations: Global Research Management, Glendale, California
Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Register for Updates
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
NCT05456425
Recruiting
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/29/2024
Locations: Global Research Mangement, Glendale, California
Conditions: Pterygium
Register for Updates
Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula
NCT04884256
Recruiting
STUDY DESIGN: Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. Duration of Treatment: 4 weeks of study treatment with 4 weeks follow-up observations. Control: Vehicle for CBT-004 (hereafter referred to as Vehicle). Masking: Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications. Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/25/2024
Locations: Global Research Management, Glendale, California
Conditions: Pinguecula
Register for Updates
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
NCT04759664
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: Innovative Clinical Research Institute, Glendale, California
Conditions: EGFRI Induced Acneiform Lesions
Register for Updates
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: The Oncology Institute of Hope and Innovation, Glendale, California
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT05218044
Recruiting
Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evaluate the potential of cryoablation as a minimally invasive alternative to surgery for small areas of DCIS by examining its ability to achieve complete ablation of DCIS within the targeted cryoablation... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/02/2023
Locations: Office of Dennis R. Holmes, M.D., F.A.C.S., Glendale, California
Conditions: Ductal Carcinoma in Situ
Register for Updates
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")
NCT05692466
Recruiting
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2023
Locations: Adventist Health Glendale, Glendale, California
Conditions: Stage III Solid Tumors, Stage IV Solid Tumors
Register for Updates
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
NCT04878003
Recruiting
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: Innovative Clinical Research Institute, Glendale, California
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Behavioral Research Specialists, LLC, Glendale, California
Conditions: Schizophrenia
Register for Updates